Plasma adiponectin is associated with ankle-brachial index in patients on haemodialysis
Corresponding Author
PAIK-SEONG LIM
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Department of Food Nutrition, Providence University, Taichung, Taiwan
Dr Paik-Seong Lim, 31 Lane 80 Yi Shu North Street, Lung Chin Hsiang, Taichung County 433, Taiwan. Email: [email protected]Search for more papers by this authorCHUEN-YUH HU
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Search for more papers by this authorMING-YING WU
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Search for more papers by this authorTSAI-KUN WU
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Search for more papers by this authorHUI-CHEN CHANG
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Search for more papers by this authorCorresponding Author
PAIK-SEONG LIM
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Department of Food Nutrition, Providence University, Taichung, Taiwan
Dr Paik-Seong Lim, 31 Lane 80 Yi Shu North Street, Lung Chin Hsiang, Taichung County 433, Taiwan. Email: [email protected]Search for more papers by this authorCHUEN-YUH HU
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Search for more papers by this authorMING-YING WU
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Search for more papers by this authorTSAI-KUN WU
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Search for more papers by this authorHUI-CHEN CHANG
Division of Renal Medicine, Tungs' Taichung Metroharbour Hospital, and
Search for more papers by this authorSUMMARY:
Background: Peripheral arterial disease (PAD) is a leading cause of morbidity in haemodialysis (HD) patients. Recent evidence suggests that adiponectin, an adipose-derived cytokine, may play a role in atherosclerosis. However, the association between plasma levels of the adiponectin and the ankle-brachial index (ABI), an indicator of the presence and severity of PAD, has not been thoroughly studied in HD patients.
Methods: The present cross-sectional study attempted to examine the relationship between plasma adiponectin and PAD in a cohort of 136 chronic HD patients. The ABI was used as an estimate of the presence of PAD. Plasma adiponectin, high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor-α and lipid profiles were measured. Logistic regression was used to estimate the association between presence of PAD and adiponectin as well as other potential risk factors.
Results: Plasma levels of adiponectin were significantly lower among patients with evidence of PAD than among those without (8.51 ± 5.75 vs 17.15 ± 11.53; P < 0.001). Univariate analysis showed a positive correlation between ABI values and plasma adiponectin levels (r = 0.369, P < 0.001), high-density lipoprotein cholesterol levels, diastolic blood pressure, Kt/V and serum phosphate. On the other hand, negative correlations between ABI and log-transformed triglyceride, hsCRP, fasting blood sugar, girth circumference and white blood cell counts were noted. Using logistic regression, plasma adiponectin was found to be associated with PAD independently of classical risk factors for atherosclerosis. In addition, models that incorporated plasma adiponectin were significantly better at predicting PAD than models limited to classical confounding factors.
Conclusion: We conclude that there was a significant inverse correlation between plasma adiponectin levels and the presence of PAD in dialysis patients. This suggests that plasma adiponectin level may have a role in the atherosclerotic process of PAD.
REFERENCES
- 1 U.S. Renal Data System. USRDS 1998 Annual Data Report. Bethesda, MD: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 1998.
- 2 O'Hare AM, Johansen KL. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2001; 12: 2838–47.
- 3 Lim PS, Chen TT, Yang SM, Chien SW, Kuo YC, Tsai Pai MA. Prevalence and clinical correlates of peripheral arterial disease in hemodialysis patients. Acta Nephrologica 2005; 19: 113–20.
- 4 Testa A, Ottavioli JN. Ankle-arm blood pressure index (AABPI) in hemodialysis patients. Arch. Mal. Coeur Vaiss. 1998; 91: 963–5.
- 5 Fishbane S, Youn S, Flaster E, Adam G, Maesaka JK. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am. J. Kidney Dis. 1996; 27: 668–72.
- 6 Ono K, Tsuchida A, Kawai H et al. Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2003; 14: 1591–8.
- 7 Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: Leptin, acylation stimulating protein, and adiponectin. Curr. Opin. Lipidol. 2002; 13: 51–9.
- 8 Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999; 257: 79–83.
- 9 Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad. Sci. 1999; 892: 146–54.
- 10 Weyer C, Funahashi T, Tanaka S. et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol Metab. 2001; 86: 930–35.
- 11 Iwashima Y, Katsuya T, Ishikawa K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318–23.
- 12 Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1595–9.
- 13 Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 85–9.
- 14 Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756–62.
- 15 Ouchi N, Kihara S, Arita Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057–63.
- 16 Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473–6.
- 17 Shoji T, Emoto M, Tabata T, et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int. 2002; 61: 2187–92.
- 18 Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H. Paradox of risk factors for cardiovascular mortality in uremia: Is a higher cholesterol level better for atherosclerosis in uremia? Am. J. Kidney Dis. 2001; 38 (4 Suppl 1): S4–7.
- 19 Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2002; 13 (1): 134–41.
- 20 Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD. Adiponectin in peritoneal dialysis patients: A comparison with hemodialysis patients and subjects with normal renal function. Am. J. Kidney Dis. 2004; 43 (6): 1047–55.
- 21 Selvin E, Erlinger TP. Prevalence and risk factors for peripheral arterial disease in the US: Results from the National Health and Nutrition Examination Survey (NHANES). 1999–2000. Circulation 2004; 110: 738–43.
- 22 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl 1): S5–20.
- 23 Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486.
- 24 Eggers PW, Gohdes D, Pugh J. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int. 1999; 56: 1524–33.
- 25 Premalatha G, Shanthirani S, Deepa R., MarkovitZ. J, Mohan V. Prevalence and risk factors of peripheral vascular disease in a selected South Indian population – The Chennai Urban Population Study (CUPS). Diabetes Care. 2000; 23: 1295–300.
- 26 Cui R., Iso H, Yamagishi K et al. Ankle-arm blood pressure index and cardiovascular risk factors in elderly Japanese men. Hypertens Res. 2003; 26: 377–82.
- 27 Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilaon PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am. Heart J. 2002; 143: 961–5.
- 28 Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481–5.
- 29 Hozawa A, Ohmori K, Kurimaya S. C-Reactive protein and peripheral artery disease among Japanese elderly: The Tsurugaya Project. Hypertens Res. 2004; 27: 955–61.
- 30 Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW. Hyperhomocysteinemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am. J. Kidney Dis. 1999; 34: 669–77.
- 31 Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55: 1899–911.
- 32 Iwashima Y, Horio T, Suzuki Y et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 2006; 188 (2): 384–90.
- 33 Dieplinger B, Poelz W, Haltmayer M, Mueller T. Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease. Clin. Chem. Laboratory Med. 2006; 44 (7): 830–3.
- 34 Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin. Chim. Acta 2004; 344: 1–12.
- 35 Jansson PA, Pellme F, Hammarstedt A et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J. 2003; 17: 1434–40.
- 36 Gil-Campos M, Cañete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin. Nutr. 2004; 23: 963–74.
- 37 Guebre-Egziabher F, Bernhard J, Geelen G, Malvoisin E, Hadj-Aissa A, Fouque D. Leptin, adiponectin, and ghrelin dysregulation in chronic kidney disease. J Ren Nutr. 2005; 15: 116–20.
- 38 Arita Y, Kihara S, Ouchi Y et al. Adipocyte-derived plasma protein, adiponectin, acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893–8.
- 39 Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women <62 years of age. Am. J. Cardiol. 1994; 74: 64–5.
- 40 Newby DE, Wright RA, Labinjoh C et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: A mechanism for arterial thrombosis and myocardial infarction. Circulation 1999; 99: 1411–5.
- 41 Gil-Nunez AC, Vivancos-Mora J. Blood pressure as a risk factor for stroke and the impact of antihypertensive treatment. Cerebrovasc. Dis. 2005; 20 (Suppl 2): 40–52.
- 42 Stenvinkel P. Inflammation in end-stage renal disease: The hidden enemy. Nephrology 2006; 11: 36–41.
Citing Literature
